Ciliopathies

Analysis of all known genes associated with ciliopathies

Ciliopathies are genetic diseases caused by a disorder of specific cell organelles called cilia. Cilia are thin projections on cells formed by cell membrane protrusions and are found on almost all cells in the human body. They are, therefore, responsible for various transport and metabolic processes, as well as participating in processing sensory perceptions in the body. In addition, cilia are involved in communication between cells, which is essential, especially during embryonic development, for a multicellular organism to develop from a fertilized egg.

The Diagnostic Panel for Ciliopathies comprises 112 genes associated with the ciliopathies disease group and is based on our proprietary, high-quality ExomeXtra® enrichment, covering all protein-coding regions as well as intronic and intergenic variants described as disease-relevant in the databases HGMD and ClinVar. In addition, the ExomeXtra® enrichment enables a genome-wide CNV calling with similar performance to array CGH. It thus provides the ideal basis for genetic diagnostics.

Are you insured in Germany? Our colleagues at the Zentrum für Humangenetik Tübingen will gladly support you!

What We Offer with the Panel for Ciliopathies

Updates

The gene selection is regularly adapted to the current scientific knowledge

Flexibility

With ExomeXtra®, gene sets addressing different diseases can be combined

Comprehensive Medical Report

Including the ACMG criteria used to classify the variants

Highest Quality

All steps are carried out in-house

Our Promise to You

Graues Icon das die Dauer symbolisiert

Fast Turnaround Time

2–4 weeks after sample receipt

Icon zur Visualisierung unseres Sicherheitsversprechens

Safety

Highest confidentiality and quality standards

Icon das Zuverlässigkeit symbolisiert

Reliability

Reliable support throughout all steps

Einfache grafische Darstellung eines Befund

Comprehensibility

Clearly prepared medical report

Your Benefits

It is possible to request single or multiple predefined gene sets. In addition to the complete analysis of the genes of the requested gene set, we extend the analysis by additional genes for differential diagnosis. We report variants of unknown significance (ACMG class 3) and pathogenic and probably pathogenic variants (ACMG classes 4 and 5) for the primarily ordered gene set. For the genes included due to differential diagnosis, we restrict the reporting to pathogenic and probably pathogenic variants (ACMG classes 4 and 5), which could be related to the indication of the person seeking advice.

The Diagnostic Panel for Ciliopathies is based on CeGaT’s ExomeXtra® enrichment. This allows, without additional sequencing, phenotypically eligible gene sets of other CeGaT panels or single genes to be additionally ordered. If you would like to assemble an individual panel, please feel free to contact us. We will be happy to support you.

In addition to the primary diagnostic assignment, the assessment of ACMG genes and pharmacogenetic profiling may also be ordered.

Method

The enrichment of the coding regions and the adjacent intronic regions is performed using an in-solution hybridization technology. The selection of the targeted regions and the design of the enrichment baits is performed in-house. High-throughput sequencing is performed on our Illumina platforms. Bioinformatic processing of the data is achieved using an in-house computer cluster.

Following data processing, our team of scientists and specialists in human genetics analyze the data and issue a medical report.

Sample Report

Information: The example report on epilepsy and brain development disorders illustrates how a report is structured.

General Information

Material

  • 1-2 ml EDTA blood (recommended sample type) or
  • 1-2 µg genomic DNA
  • Order Form with declaration of consent

Here you can find more information on how to ship your sample safely.

Costs

The prices for our human genetic diagnostics depend on the size of the selected diagnostic panel and the selected gene sets. All prices include sequencing, bioinformatic analysis, and issuing of a medical report by our team of experts in human genetic diagnostics.

Diagnostic Process

Icon Prozessablauf

Counseling & Test Selection

Icon Prozessablauf
Icon Prozessablauf

Sampling & Shipment

Icon Prozessablauf
Icon Prozessablauf

Sample Analysis

Icon Prozessablauf
Icon Prozessablauf

Medical Report & Counseling

Gene Sets – Ciliopathies

Primary Ciliary Dyskinesia (CIL01, 39 Genes)

ARMC4, CCDC103, CCDC114, CCDC151, CCDC39, CCDC40, CCDC65, CCNO, CFAP298, CFAP300, DNAAF1, DNAAF2, DNAAF3, DNAAF4, DNAAF5, DNAH11, DNAH5, DNAH8, DNAI1, DNAI2, DNAJB13, DNAL1, DRC1, GAS8, HYDIN, INVS, LRRC6, NME8, OFD1, PIH1D3, RPGR, RSPH1, RSPH3, RSPH4A, RSPH9, SPAG1, STK36, TTC25, ZMYND10

Joubert Syndrome (CIL02, 46 Genes)

AHI1, ARL13B, ARL3, ARMC9, B9D1, B9D2, C2CD3, CC2D2A, CELSR2, CEP104, CEP120, CEP164, CEP290, CEP41, CPLANE1, CSPP1, EXOC8, FAM149B1, HYLS1, IFT172, IFT74, INPP5E, KIAA0556, KIAA0586, KIAA0753, KIF7, MKS1, NPHP1, OFD1, PDE6D, PIBF1, POC1B, RPGRIP1L, SUFU, TCTN1, TCTN2, TCTN3, TMEM107, TMEM138, TMEM216, TMEM218, TMEM231, TMEM237, TMEM67, TTC21B, ZNF423

Bardet-Biedl Syndrome (CIL03, 32 Genes)

ALMS1, ARL6, BBIP1, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5, BBS7, BBS9, C8orf37, CCDC28B, CEP164, CEP19, CEP290, CEP41, IFT172, IFT27, IFT74, KIF7, LZTFL1, MKKS, MKS1, NPHP1, SDCCAG8, TMEM67, TRAPPC3, TRIM32, TTC21B, TTC8, WDPCP

Senior-Loken Syndrome (CIL04, 13 Genes)

CEP164, CEP290, INVS, IQCB1, NPHP1, NPHP3, NPHP4, SCLT1, SDCCAG8, TMEM67, TRAF3IP1, WDR19, ZNF423

Gene Directory – Panel for Ciliopathies

AHI1, ALMS1, ARL13B, ARL3, ARL6, ARMC9, B9D1, B9D2, BBIP1, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5, BBS7, BBS9, C2CD3, CC2D2A, CCDC103, CCDC28B, CCDC39, CCDC40, CCDC65, CCNO, CELSR2, CEP104, CEP120, CEP164, CEP19, CEP290, CEP41, CFAP298, CFAP300, CFAP418, CPLANE1, CSPP1, DNAAF1, DNAAF11, DNAAF2, DNAAF3, DNAAF4, DNAAF5, DNAAF6, DNAH11, DNAH5, DNAH8, DNAI1, DNAI2, DNAJB13, DNAL1, DRC1, EXOC8, FAM149B1, GAS8, HYDIN, HYLS1, IFT172, IFT27, IFT74, INPP5E, INVS, IQCB1, KATNIP, KIAA0586, KIAA0753, KIF7, LZTFL1, MKKS, MKS1, NME8, NPHP1, NPHP3, NPHP4, ODAD1, ODAD2, ODAD3, ODAD4, OFD1, PDE6D, PIBF1, POC1B, RPGR, RPGRIP1L, RSPH1, RSPH3, RSPH4A, RSPH9, SCLT1, SDCCAG8, SPAG1, STK36, SUFU, TCTN1, TCTN2, TCTN3, TMEM107, TMEM138, TMEM216, TMEM218, TMEM231, TMEM237, TMEM67, TRAF3IP1, TRAPPC3, TRIM32, TTC21B, TTC8, WDPCP, WDR19, ZMYND10, ZNF423

Additional Services

HLA-Typing (HLA01)

HLA class I (Gene A, B, C) and HLA class II (Gene DPA1, DPB1, DQA1, DQB1, DRB1, DRB3, DRB4, DRB5)

ACMG Genes

Genetic variation may sometimes be identified, which does not fit within the scope of the requested genetic analysis (so-called secondary findings). The reporting of these variants is limited to pathogenic alterations (ACMG classes 4 and 5) within selected genes, for which a treatment or course of action exists for you or your family (according to the current guidelines of the American College of Medical Genetics and Genomics).

Details on genes and associated diseases can be found here

Pharmacogenetics

Pharmacogenetic analysis detects genetic changes that affect the effectiveness of drugs. Genetic variants that affect proteins responsible for the metabolism of substances can significantly change their tolerance and efficacy. These drugs include, among others, antidepressants, pain relievers, neuroleptics, chemotherapeutics, AIDS drugs, thrombosis drugs, anesthetics, beta-blockers, or statins.

The reduced activity of a specific enzyme can lead to an increased drug level in the standard dosage, which is often associated with undesirable side effects. With drugs that are only activated by metabolism, the therapeutic effect can be completely absent. Likewise, due to the resulting increased rate of degradation of the medicinal substance, an increased enzyme activity leads to inadequate effectiveness of the therapy.

The pharmacogenetics option analyzes known variants in twenty-one genes involved in the metabolism of drugs. If specific gene variants occur, the treating doctor can adapt the therapy individually. The pharmacogenetic analysis can minimize serious side effects and helps to avoid failure of the treatment.

Details on genes and more infomation can be found here

Downloads

Order Form CIL
Sample Report EPI

* The example report on epilepsy and brain development disorders illustrates how a report is structured.

Contact Us

Do you have a question, or are you interested in our service?

The fields marked with (*) are mandatory and must be completed.

Diagnostic Support

We will assist you in selecting the diagnostic strategy – for each patient.

Keimbahn Team der CeGaT